Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group.
Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group.
复制标题
转移性神经母细胞瘤儿童的多药化疗：儿童癌症研究组的报告。
DOI：
--
复制
发表时间：
1979
期刊：
影响因子：
--
通讯作者：
D. Hammond
中科院分区：
文献类型：
--
作者：
J. Finklestein;M. Klemperer;Evans Ae;I. Bernstein;S. Leikin;Samuel R. McCreadie;J. Grosfeld;R. Hittle;J. Weiner;H. Sather;D. Hammond
在过去的10-15年中，转移性神经母细胞瘤儿童的总体生存率没有显着改善。从1971年到1975年，104名符合条件的患者参加了儿童癌症研究组（CCSG）对新诊断的IV期神经母细胞瘤病例进行的两项临床研究。评价了两项研究的患者数据中环磷酰胺、咪唑甲酰胺和长春新碱以及这些相同药物加阿霉素的活性。通过连续测量肿瘤大小评价缓解。84例患者出现完全或部分缓解。两项研究的中位生存期的生命表估计值为11-12个月（所有患者）和13-18个月（应答者），与之前CCSG研究的结果相同。然而，这些研究中患者的长期生存率与之前三项CCSG研究的结果相比有显著提高。小于1岁或大于6岁的儿童在诊断时显示出比中间年龄组显著改善的生存模式。这表明，有必要考虑诱导反应模式和诊断时的年龄规划的维护程序，使无应答者可以及早识别，并考虑与新的药物或积极的多模式治疗。
During the past 10-15 years there has not been a significant improvement in the overall survival of children with metastatic neuroblastoma. From 1971 through 1975, 104 eligible patients were entered on two clinical studies for newly diagnosed cases of stage IV neuroblastoma by the Childrens Cancer Study Group (CCSG). Patient data from both studies were evaluated for activity of cyclophosphamide, imidazole carboxamide, and vincristine and of these same agents plus adriamycin. Response was evaluated by serial measurements of tumor size. Eighty-four patients experienced a complete or partial response. The life-table estimate of median survival on both studies was 11–12 months for all patients and 13-18 months for responders, unchanged from the results of previous CCSG studies. Long-term survival, however, for patients on these studies demonstrates a significant increase compared with results reported from the three previous CCSG studies. Children less than 1 year or greater than 6 years of age at diagnosis showed a significantly improved survival pattern over the intermediate age group. It is suggested that there is a need to consider the induction response pattern and age at diagnosis when planning a maintenance program so that nonresponders can be identified early and considered for treatment with new agents or aggressive multimodal therapy.